GoodRX and CVS Caremark partner to offer discounted prescriptions

CVS Caremark and GoodRX are partnering to offer patients discounts on their pharmaceutical needs.

The companies announced the launch of the Caremark Cost Saver program on July 12. As part of the program, eligible Caremark members who carry commercial insurance will have GoodRX’s discounted pricing applied automatically to their prescription purchases.

Customers will not be required to take any additional steps in order to gain access to the discounted prescriptions, and all transactions will be automatically applied to their deductibles, according to the announcement.

David Joyner, executive vice president of CVS Health and president of Caremark, said that the new collaboration will enable the partners to “dynamically shop for the best price” on their customers’ behalf.

“By lowering out-of-pocket costs for our clients’ members, Caremark Cost Saver will help patients afford to take their medicine as directed," Joyner said in a prepared statement.

Scott Wagner, interim CEO of GoodRx, added that the partnership will make a “meaningful difference” for the millions of Americans who use CVS Caremark’s services.

“Healthcare only works when patients can afford it, which is why we are excited to work with CVS Caremark to combine their great value with automatic access to our low prices on prescriptions,” Wagner said. “Through this program, patients don’t have to choose between using their pharmacy benefit or using GoodRx to save on their prescriptions—now they can do both right at the counter so they have confidence they are always paying the lowest available price.”

The program is slated to take effect starting on January 1, 2024.

Read the full announcement here.

Hannah murhphy headshot

In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.